Study authors performed a post hoc pooled analysis of data from 10 trials to assess the safety and efficacy of umeclidinium/vilanterol in elderly symptomatic patients with COPD.
The drug consists of fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered via an Ellipta dry powder inhaler.
Study authors concluded, "Combining tiotropium and olodaterol did not reduce exacerbation rate as much as expected compared with tiotropium alone."
Results demonstrated that after indacaterol-glycopyrronium treatment, left-ventricular end-diastolic volume increased from a mean 55.46mL/m2 (SD 15.89) at baseline to a least-squares (LS) mean of 61.76mL/m2 (95% CI 57.68-65.84).
Long-term ICS exposure at high doses was associated with a modest but significant increase in the risk of hip or upper extremity fractures.
Adults treated with Lonhala Magnair showed statistically significant and clinically important changes from baseline in trough forced expiratory volume in 1 second (FEV1) at Week 12 vs placebo.
Trelegy Ellipta combines fluticasone furoate, an inhaled corticosteroid with umeclidinium, an anticholinergic and vilanterol, a long-acting β2-adrenergic agonist (LABA).
The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD.
Clinical guidelines currently recommend LABA/LAMA therapy as an alternative to LABA/ICS but evidence on the comparative effectiveness of these combination therapies for COPD is limited.